SARTORIUS STED BIO : Sartorius Stedim Biotech: Q1 2012 Results
04/24/2012| 05:55am US/Eastern
The Sartorius Stedim Biotech Group's (Paris:DIM) Investor Relations
Release on the Q1 2012 results is now available at www.sartorius.com.
It contains the following information:
- Business development for the first three months and the 2012 forecast
for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended March 31, 2012
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment
and services for the development, quality assurance and production
processes of the biopharmaceutical industry. Its integrated solutions
covering fermentation, cell cultivation, filtration, purification, fluid
management and lab technologies are supporting the biopharmaceutical
industry around the world to develop and produce drugs safely, timely
and economically. Sartorius Stedim Biotech focuses on single-use
technologies and value-added services to meet the rapidly changing
technology requirements of the industry it serves. Strongly rooted in
the scientific community and closely allied with customers and
technology partners, the company is dedicated to its philosophy of
"turning science into solutions."
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on
the Eurolist of Euronext Paris. With its own manufacturing and R&D sites
in Europe, North America and Asia and a global network of sales
companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key
manufacturing and R&D site is in Germany. The company employs approx.
2,850 people, and in 2011 earned sales revenue of 477.3 million euros.
Sartorius Corporate Administration GmbH
Vice President of Corporate Communications and Investor Relations
Fax: +49(0)551/ 308-3410
Theisen, Director Investor Relations
Phone: +49(0)551/ 308-1668
© Business Wire 2012